REFERENCES
- LaMattina KC. Overview of uveitis. http://www.merckmanuals.com/professional/eye-disorders/uveitis-and-related-disorders/overview-of-uveitis#v956773. Accessed October 16, 2017.
- Mayo Clinic. Uveitis: Complications. https://www.mayoclinic.org/diseases-conditions/uveitis/basics/complications/con-20026602
- Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500. discussion 500. doi:10.1016/j.ophtha.2003.06.014.
- Lee RW, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond). 2012;26(1):17–28. doi:10.1038/eye.2011.255.
- Siddique SS, Suelves AM, Baheti U, Foster CS. Glaucoma and uveitis. Surv Ophthalmol. 2013;58(1):1–10. doi:10.1016/j.survophthal.2012.04.006.
- Gomes Bittencourt M, Sepah YJ, Do DV, et al. New treatment options for noninfectious uveitis. Dev Ophthalmol. 2012;51:134–161. doi:10.1159/000336338.
- Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
- Gallego-Pinazo R, Dolz-Marco R, Martinez-Castillo S, Arevalo JF, Diaz-Llopis M. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets. 2013;12:38–45.
- Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect. 2013;3(1):64. doi:10.1186/1869-5760-3-64.
- Thorne JE, Skup M, Tundia N, et al. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol. 2016;94(5):e331–339. doi:10.1111/aos.12987.
- Rice JB, White AG, Scarpati LM, Wan GJ, Nelson WW. The burden of non-infectious intraocular inflammatory eye diseases: a systematic literature review. Curr Med Res Opin. 2018;34(12):2095–2103.
- Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88(9):1159–1162. doi:10.1136/bjo.2003.037226.
- Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–848.
- OptumHealth Care Solutions Inc. Employer data warehouse. https://www.optum.com/solutions/prod-nav/benefit-analytics.html
- Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303(23):2359–2367. doi:10.1001/jama.2010.796.
- Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med. 2009;169(5):480–488. doi:10.1001/archinternmed.2008.587.
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
- Medicare.gov. Medicare costs at a glance. https://www.medicare.gov/your-medicare-costs/medicare-costs-at-a-glance
- Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med. 2000;42(6):588–596.
- Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014;37(3):651–658. doi:10.2337/dc13-2176.
- Dick AD, Tundia N, Sorg R, et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2016;123(3):655–662. doi:10.1016/j.ophtha.2015.10.028.